Amylyx Pharmaceuticals, Inc.AMLXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover GP II, LLC | 6.80% | 4.6M | — | 2024-08-26 |
| Perceptive Advisors LLC | 6.50% | 4.5M | ▲ +3.70pp | 2024-10-25 |
| Panacea Innovation Limited | 6.20% | 4.2M | — | 2024-03-11 |
| THE GOLDMAN SACHS GROUP, INC. | 5.40% | 3.7M | — | 2023-06-09 |
| The Vanguard Group | 4.53% | 3.1M | flat | 2024-11-12 |
| Viking Global Investors LP | 4.40% | 3.0M | — | 2024-02-14 |
| Point72 Asset Management, L.P. | 4.10% | 2.8M | ▼ -0.60pp | 2024-02-14 |
| BlackRock, Inc. | 3.90% | 2.7M | ▼ -2.00pp | 2024-07-08 |
| Morningside Venture Investments Limited | 3.43% | 2.3M | ▼ -3.43pp | 2023-10-04 |
Insider Transactions
Net 90d: −$1.16M · buys $0 / sells $1.16MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-05 | Bedrosian Camille L | Chief Medical Officer | Grant | 96.0K | $0.00 | $0 |
| 2026-03-05 | FRATES JAMES M | Chief Financial Officer | Grant | 96.0K | $0.00 | $0 |
| 2026-03-05 | Cohen Joshua B | Co-Chief Executive Officer | Grant | 248.9K | $0.00 | $0 |
| 2026-03-05 | Gina Mazzariello | Chief Legal Officer | Grant | 74.7K | $0.00 | $0 |
| 2026-03-05 | Klee Justin B. | Co-Chief Executive Officer | Grant | 248.9K | $0.00 | $0 |
| 2026-03-02 | Klee Justin B. | Co-Chief Executive Officer | Sell (open market) | 29.3K | $14.47 | $423.8K |
| 2026-03-02 | Cohen Joshua B | Co-Chief Executive Officer | Sell (open market) | 29.3K | $14.48 | $424.1K |
| 2026-03-02 | Bedrosian Camille L | Chief Medical Officer | Sell (open market) | 6.5K | $14.58 | $94.2K |
| 2026-03-02 | Gina Mazzariello | Chief Legal Officer | Sell (open market) | 6.8K | $14.52 | $99.4K |
| 2026-03-02 | FRATES JAMES M | Chief Financial Officer | Sell (open market) | 7.9K | $14.52 | $114.9K |
1–10 of 10